Inna Chernoglaz
Medical · Brooklyn, NYNPI 1225226756
Payments from drug & device makers
Across 234 payments — averaging $20.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$559
- Lilly USA, LLC$425
- Amgen$394
- Scilex Pharmaceuticals Inc.$331
- Ardelyx, Inc.$210
- plus $2K from 22 others
What the payments were for
- Food & beverage$4,829100%
- Gifts$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 69 | $1,368 |
| Novo Nordisk | 27 | $559 |
| Lilly USA, LLC | 19 | $425 |
| Amgen(2 entities) | 19 | $394 |
| Scilex Pharmaceuticals Inc. | 17 | $331 |
| Ardelyx, Inc. | 7 | $210 |
| Amarin Pharma, Inc. | 9 | $194 |
| Ironwood Pharmaceuticals, Inc | 9 | $191 |
| Astellas Pharma US Inc | 8 | $160 |
| Novartis | 7 | $124 |
| E.r. Squibb & Sons, L.L.C. | 6 | $92 |
| Esperion Therapeutics, Inc. | 4 | $85 |
| Arbor Pharmaceuticals, Inc. | 4 | $84 |
| Abbott | 3 | $74 |
| Pfizer | 4 | $70 |
| Nestle Healthcare Nutrition Inc. | 3 | $61 |
| Sumitomo Pharma America, Inc. | 3 | $60 |
| Johnson & Johnson | 2 | $58 |
| Exact Sciences | 2 | $55 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Vistapharm, Inc. | 2 | $28 |
| AstraZeneca | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Shield Therapeutics Inc | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $24 |
| Vivus LLC | 1 | $19 |
| Vifor Pharma, Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $17 |
How this compares
$4,829 in reported general payments places this provider in the 85th percentile of 2,395 medical providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 211 | $258,458 |
| Diclofenac Sodium | 360 | $231,361 |
| VascepaIcosapent Ethyl | 407 | $142,154 |
| LinzessLinaclotide | 253 | $135,624 |
| ZenpepLipase/Protease/Amylase | 95 | $125,352 |
| UbrelvyUbrogepant | 41 | $94,866 |
| MyrbetriqMirabegron | 163 | $74,822 |
| EliquisApixaban | 111 | $74,051 |
| Repatha SureclickEvolocumab | 122 | $65,110 |
| OzempicSemaglutide | 73 | $64,911 |
| ProliaDenosumab | 29 | $48,642 |
| JardianceEmpagliflozin | 64 | $36,895 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 36 | $34,152 |
| RexultiBrexpiprazole | 18 | $30,434 |
| TradjentaLinagliptin | 55 | $30,037 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Ubrelvy, Restasis, Qulipta | $1,368 | $543,397585 claims |
| Aimmune Therapeutics, Inc.Zenpep | $24 | $125,35295 claims |
| Novo NordiskOzempic, Rybelsus | $559 | $86,98697 claims |
| Astellas Pharma US IncMyrbetriq | $160 | $74,822163 claims |
| PfizerEliquis | $70 | $74,051111 claims |
| AmgenProlia | $394 | $48,64229 claims |
| NovartisEntresto, Exelon | $124 | $36,64045 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $84 | $35,698102 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $425 | $26,50728 claims |
| AstraZenecaCrestor, Nexium | $28 | $23,60488 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $331 | $18,99844 claims |
| Johnson & JohnsonXarelto | $58 | $17,57021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,395 medical providers in New York.
Other medical in Brooklyn
- Carl ClarkeBrooklyn$116K
- Catherine SekanskyBrooklyn$28K
- Phillip ScottiBrooklyn$22K
- Anna GorelikBrooklyn$15K
- Vita OklanderBrooklyn$13K
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Maureen ThyneNew York$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.